Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of BTX stock opened at $0.21 on Monday. The business’s fifty day moving average price is $2.12 and its 200 day moving average price is $1.79. The firm has a market capitalization of $12.07 million, a PE ratio of -0.09 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.